TRIM60P5Y
associated omics dataQ-omics provides the consensus-scored TRIM60P5Y profile across patient tissues and cancer cell-line models. TRIM60P5Y expression is associated with patient survival in 1 of 34 cancer types, with the highest sampling consensus in LUAD.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM60P5Y — synthetic lethality, tumor antigen, and pembrolizumab response.
View premium →Survival associations
This table summarizes TRIM60P5Y survival associations across molecular data types. TRIM60P5Y RNA expression shows survival associations in the most cancer types (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM60P5Y RNA expression–survival associations across cancer types. High TRIM60P5Y expression shows unfavorable associations in LUAD. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for TRIM60P5Y RNA expression.
